Tisotumab Vedotin
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 105 publications
Tisotumab vedotin-associated Stevens-Johnson syndrome in a patient with recurrent vulvar cancer: Vulnerability and antibody drug conjugate toxicity considerations.
Journal: Gynecologic oncology reports
Published: February 13, 2026
Molecular Targets of Cervical Cancer and Its Microenvironment: Advances in Treatment.
Journal: Cancers
Published: December 30, 2025
Latest Drug Therapies for Cervical Cancer
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: December 24, 2025
Cost-effectiveness of second- or third-line treatment with tisotumab vedotin for metastatic or recurrent cervical cancer.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: December 12, 2025
Advances in Screening, Immunotherapy, Targeted Agents, and Precision Surgery in Cervical Cancer: A Comprehensive Clinical Review (2018-2025).
Journal: Current oncology (Toronto, Ont.)
Published: November 23, 2025
New developments in the treatment of cervical cancer in 2026.
Journal: Current opinion in obstetrics & gynecology
Published: November 17, 2025
Antibody-Drug Conjugates in Gynecologic Oncology: Advances, Challenges, and Future Directions.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: November 03, 2025
Antibody-Drug Conjugates for the Treatment of Gynecologic Cancer: A Review of the Current Evidence and Clinical Application.
Journal: Hematology/oncology clinics of North America
Published: October 31, 2025
Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: September 19, 2025
Recent therapeutic advances in gynecologic oncology: evolving roles of immunotherapy, antibody-drug conjugates, and clinical trial innovations.
Journal: Frontiers in oncology
Published: September 01, 2025
Recent advances in antibody-drug conjugates for metastatic castration-resistant prostate cancer
Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
Published: August 27, 2025
Clinical pharmacologic considerations for antibody-drug conjugate in gynecologic cancers.
Journal: Expert review of clinical pharmacology
Published: July 15, 2025
Last Updated: 04/28/2026